A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

NCT07286149 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Neoplasm Malignant

Interventions

DRUG: MK-1084
BIOLOGICAL: Patritumab deruxtecan
BIOLOGICAL: Sacituzumab tirumotecan
BIOLOGICAL: Cetuximab
DRUG: Rescue Medications

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]